The European market for oral solid dosage contract manufacturing was valued at USD 6,280.24 million in 2023. It is projected to grow at a compound annual growth rate (CAGR) of approximately 5.5% from 2023 to 2032, reaching a valuation of USD 10,441.43 million by 2032.
The growth is primarily driven by the increasing demand for oral solid dosage pharmaceuticals, such as tablets and capsules. Key drivers include the complexity of emerging drug compounds, advancements in drug delivery technologies, the need for enhanced bioavailability, patient compliance, and a rising demand for generic medications. The stringent regulatory environment in Europe also plays a significant role.
Major participants in the market include Catalent Inc., Lonza Group, Piramal Pharma Solutions, Aenova, Jubilant, Boehringer Ingelheim, AbbVie Contract Manufacturing, Patheon, Recipharm, Next Pharma AB, Siegfried AG, and Corden Pharma. These companies are making significant investments in the development of oral solid dosage forms.
Europe’s aging population and the increase in chronic diseases are spurring higher demand for medications, including oral solid dosages. The pharmaceutical industry’s shift towards cost-effectiveness and production efficiency is leading to increased outsourcing to contract manufacturers. Additionally, there’s a growing focus on specialized therapeutic areas like oncology and neurology, and strategic collaborations between pharmaceutical companies and CMOs are also contributing to market growth.